SGLT2 inhibitors: Exploring the effects in humans and horses

Abstract

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are human antidiabetic drugs that are increasingly used in equine practice for the management of hyperinsulinaemia and hyperinsulinaemia-associated laminitis. However, the understanding of SGLT2i use in horses is in its infancy compared to human medicine. This review article aims to briefly examine the literature in both species, highlighting current knowledge gaps, potential similarities in therapeutic outcomes and possible adverse effects.